Psychiatric healthcare resource utilization following initiation of aripiprazole once-monthly: a retrospective real-world study

References

• National Institutes of Mental Health. Schizophrenia. Bethesda (MD): National Institutes of Health; 2022. Available from: NIMH » Schizophrenia (nih.gov.)
   Google Scholar
• American Psychiatric Society. Diagnostic and statistical manual of mental disorders. Washington (DC): American Psychiatric Association; 2013. Available from: https://cdn.websiteeditor.net/30f11123991548a0af708722d458e476/files/uploaded/DSM%2520V.pdf
   Google Scholar
• Blanco C, Compton WM, Saha TD, et al. Epidemiology of DSM-5 bipolar I disorder: results from the national epidemiologic survey on alcohol and related conditions-III. J Psychiatr Res. 2017;84:310–317.
   PubMed Web of Science ®Google Scholar
• Saklad SR, Kreys TJ, Phan SV. Aripiprazole long-acting (ABILIFY MAINTENA) for treatment of schizophrenia. Ment Health Clin. 2015;5(4):149–161.
   Google Scholar
• Vieta E, Berk M, Schulze TG, et al. Bipolar disorders. Nat Rev Dis Primers. 2018;4:18008.
   PubMed Web of Science ®Google Scholar
• Mahabaleshwarkar R, Lin D, Joshi K, et al. Characteristics and healthcare burden of patients with schizophrenia treated in a US integrated healthcare system. J Ment Health Policy Econ. 2021;24(2):47–59.
   PubMed Web of Science ®Google Scholar
• Bessonova L, Ogden K, Doane MJ, et al. The economic burden of bipolar disorder in the United States: a systematic literature review. Clinicoecon Outcomes Res. 2020;12:481–497.
   PubMed Web of Science ®Google Scholar
• Donovan JM, Steinberg SM, Sabin JE. Managed mental health care: an academic seminar. Am Psychother Theory Res Pract Train. 1994;31(1):201–207.
   Web of Science ®Google Scholar
• Cramer JA, Rosenheck R. Compliance with medication regimens for mental and physical disorders. Psychiatr Serv. 1998;49(2):196–201.
   PubMed Web of Science ®Google Scholar
• Patel MX, Taylor M, David AS. Antipsychotic long-acting injections: mind the gap. Br J Psychiatry. 2009;195(S52):S1–S4.
   PubMedGoogle Scholar
• Goff DC, Hill M, Freudenreich O. Strategies for improving treatment adherence in schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2010;7(Suppl 2):20–26.
   Google Scholar
• Lingam R, Scott J. Treatment non-adherence in affective disorders. Acta Psychiatr Scand. 2002;105(3):164–172.
   PubMed Web of Science ®Google Scholar
• Haddad PM, Brain C, Scott J. Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies. Patient Relat Outcome Meas. 2014;5:43–62.
   PubMedGoogle Scholar
• Lachaine J, Lapierre ME, Abdalla N, et al. Impact of switching to long-acting injectable antipsychotics on health services use in the treatment of schizophrenia. Can J Psychiatry. 2015;60(3 Suppl 2):S40–S47.
   PubMedGoogle Scholar
• Kim HO, Seo GH, Lee BC. Real-world effectiveness of long-acting injections for reducing recurrent hospitalizations in patients with schizophrenia. Ann Gen Psychiatry. 2020;19:1.
   PubMed Web of Science ®Google Scholar
• Berk L, Hallam KT, Colom F, et al. Enhancing medication adherence in patients with bipolar disorder. Hum Psychopharmacol. 2010;25(1):1–16.
   PubMed Web of Science ®Google Scholar
• Colom F, Vieta E, Tacchi MJ, et al. Identifying and improving non-adherence in bipolar disorders. Bipolar Disord. 2005;7(s5):24–31.
   PubMedGoogle Scholar
• Leucht S, Heres S. Epidemiology, clinical consequences, and psychosocial treatment of nonadherence in schizophrenia. J Clin Psychiatry. 2006;67(Suppl 5):3–8.
   PubMed Web of Science ®Google Scholar
• Gianfrancesco FD, Sajatovic M, Rajagopalan K, et al. Antipsychotic treatment adherence and associated mental health care use among individuals with bipolar disorder. Clin Ther. 2008;30(7):1358–1374.
   PubMed Web of Science ®Google Scholar
• Rascati KL, Richards KM, Ott CA, et al. Adherence, persistence of use, and costs associated with second-generation antipsychotics for bipolar disorder. Psychiatr Serv. 2011;62(9):1032–1040.
   PubMed Web of Science ®Google Scholar
• Johnson FR, Ozdemir S, Manjunath R, et al. Factors that affect adherence to bipolar disorder treatments: a stated-preference approach. Med Care. 2007;45(6):545–552.
   PubMed Web of Science ®Google Scholar
• Aripiprazole once-monthly in patients with schizophrenia. ClinicalTrials.gov identifier: NCT01959035. Rockville (MD): US Food and Drug Administration. [updated 2017 Mar 17; accessed 2022 Jun 2]. Available from: https://clinicaltrials.gov/ct2/show/NCT01959035
   Google Scholar
• Calabrese JR, Jin N, Johnson B, et al. Aripiprazole once-monthly as maintenance treatment for bipolar I disorder: a 52-week, multicenter, open-label study. Int J Bipolar Disord. 2018;6(1):14.
   PubMed Web of Science ®Google Scholar
• Kane JM, Schooler NR, Marcy P, et al. Effect of long-acting injectable antipsychotics vs usual care on time to first hospitalization in early-phase schizophrenia: a randomized clinical trial. JAMA Psychiatry. 2020;77(12):1217–1224.
   PubMed Web of Science ®Google Scholar
• Kane JM, Sanchez R, Zhao J, et al. Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly for the management of schizophrenia. J Med Con. 2013;16(7):917–925.
   Google Scholar
• Patel R, Wee SN, Ramaswamy R, et al. NeuroBlu, an electronic health record (EHR) trusted research environment (TRE) to support mental healthcare analytics with real-world data. BMJ Open. 2022;12(4):e057227.
   PubMed Web of Science ®Google Scholar
• Suzuki T. A further consideration on long-acting injectable versus oral antipsychotics in the treatment of schizophrenia: a narrative review and critical appraisal. Expert Opin Drug Deliv. 2016;13(2):253–264.
   PubMed Web of Science ®Google Scholar
• Kirson NY, Weiden PJ, Yermakov S, et al. Efficacy and effectiveness of depot versus oral antipsychotics in schizophrenia: synthesizing results across different research designs. J Clin Psych. 2013;19;74(6):6018.
   Google Scholar
• Lafeuille MH, Dean J, Carter V, et al. Systemic review of long-acting injectables versus oral atypical antipsychotics on hospitalization in schizophrenia. Curr Med Res Opin. 2014;30(8):1643–1655.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609.
   PubMed Web of Science ®Google Scholar
• Yan T, Greene M, Chang E, et al. Medication adherence and discontinuation of aripiprazole once-monthly 400 mg (AOM 400) versus oral antipsychotics in patients with schizophrenia or bipolar I disorder: a real-world study using US claims data. Adv Ther. 2018;35(10):1612–1625.
   PubMed Web of Science ®Google Scholar
• Iwata N, Inagaki A, Sano H, et al. Treatment persistence between long-acting injectable versus orally administered aripiprazole among patients with schizophrenia in a real-world clinical setting in Japan. Adv Ther. 2020;37(7):3324–3336.
   PubMed Web of Science ®Google Scholar
• Yan T, Greene M, Chang E, et al. All-cause hospitalization and associated costs in patients with schizophrenia or bipolar disorder initiating long-acting injectable antipsychotics. Curr Med Res Opin. 2018;34(1):41–47.
   PubMed Web of Science ®Google Scholar
• Yan T, Greene M, Chang E, et al. Impact of initiating long-acting injectable antipsychotics on hospitalization in patients with bipolar I disorder. J Comp Eff Res. 2018;7(11):1083–1093.
   PubMed Web of Science ®Google Scholar